奥沙利铂联合卡培他滨新辅助治疗进展期胃癌疗效分析

Analysis of Efficacy of Oxaliplatin Combined With Capecitabine Neoadjuvant Therapy in the Treatment of Advanced Gastric Cancer

目的探析奥沙利铂联合卡培他滨新辅助治疗进展期胃癌的临床效果。方法选取50例进展期胃癌患者随机将患者分成实验组与对照组,每组各25例。对照组先施行手术,术后再进行化疗;实验组先采取奥沙利铂联合卡培他滨新辅助治疗,再进行手术,观察两组患者的化疗结果。结果实验组化疗总有效率为84%,对照组为56%;实验组骨髓抑制、胃肠道反应等不良反应发生率低于对照组,且它不良反应的严重程度也不及对照组,差异具有统计学意义,P<0.05,具有统计学意义。结论奥沙利铂联合卡培他滨新辅助治疗进展期胃癌疗效果显著,副作用少。

Objective To analyze clinical effect of capecitabine combined with oxaliplatin neoadjuvant for the treatment of advanced gastric cancer. Methods 50 cases of patients with advanced gastric cancer were randomly selected and were divided into experimental group and control group, 25 cases in each group. Control group before surgery, postoperative chemotherapy again; Experim. ental group take oxaliplatin into joint capecitabine neoadjuvant therapy, surgery again, observe the result of two groups of patients with chemotherapy. Results The total effective rate of chemotherapy was 84%, the control group is 56%; Experimental bone marrow suppression, gastrointestinal reactions, such as lower incidence of adverse reactions to the control group, and it is also the severity of the adverse reaction is less than the control group, P 〈 0.05, with statistical significance. Conclusion Capecitabine combined with oxaliplatin into new auxiliary treatment of advanced gastric cancer therapy effect is remarkable, less side effect.